These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18925695)

  • 1. Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.
    Korać P; Dominis M
    Croat Med J; 2008 Oct; 49(5):618-24. PubMed ID: 18925695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
    Gualco G; Weiss LM; Harrington WJ; Bacchi CE
    Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
    Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
    Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
    Bellas C; García D; Vicente Y; Kilany L; Abraira V; Navarro B; Provencio M; Martín P
    PLoS One; 2014; 9(6):e98169. PubMed ID: 24887414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
    Barrans SL; Fenton JA; Banham A; Owen RG; Jack AS
    Blood; 2004 Nov; 104(9):2933-5. PubMed ID: 15238418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
    Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
    J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
    He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
    Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
    Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
    Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles.
    Madan R; Gormley R; Dulau A; Xu D; Walsh D; Ramesh KH; Cannizaro L; Tamas EF; Kumar P; Sparano J; LeValley A; Xue X; Bhattacharyya PK; Ioachim HL; Ratech H
    Mod Pathol; 2006 Mar; 19(3):438-46. PubMed ID: 16444194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.